Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ: ENVB )

0.3501 -0.0069 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,788,964
Open 0.3600
Bid (Size) 0.3737 (20)
Ask (Size) 0.3901 (4)
Prev. Close 0.3570
Today's Range 0.3500 - 0.3710
52wk Range 0.2955 - 2.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire

Performance

YTD
-10.23%
-10.23%
1 Month
-4.21%
-4.21%
3 Month
-20.52%
-20.52%
6 Month
-27.81%
-27.81%
1 Year
-68.74%
-68.74%

More News

Read More
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
Via Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
From Enveric Biosciences, Inc.
Via Business Wire
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Via Benzinga
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Via Benzinga
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Via Benzinga
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Via Benzinga
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback